R

Roche

Doing Now What Patients Need Next

Basel, Switzerland (US: South SF, Indianapolis)
100,000+

About Roche

Industry: Pharmaceuticals/Diagnostics
Founded: 1896
Founders: Fritz Hoffmann-La Roche
Status: Public (SWX: ROG)

Funding & Growth

Total Raised: N/A
Valuation: $230B+ market cap
Stage: Public
Key Investors:
Public markets

Pros

  • Combined pharma and diagnostics strength
  • Genentech subsidiary for US pharma
  • Leader in personalized healthcare
  • Strong scientific culture
  • Good work-life balance

Cons

  • Swiss headquarters (timezone)
  • Large company bureaucracy
  • Some overlap with Genentech
  • Complex matrix organization

🏢 Working Here

Roche's computational biology operations span multiple global sites - Basel (Switzerland), South San Francisco (Genentech), and Penzberg (Germany).

As the world's largest biotech company, Roche offers unparalleled scale in pharmaceuticals and diagnostics.

Bioinformaticians work across Roche Pharma Research (RRED), Roche Diagnostics, and Genentech (wholly owned subsidiary).

Teams focus on personalized healthcare, combining diagnostic tests with targeted therapies.

The culture is highly international with scientists from 100+ countries.

Work involves analyzing clinical trial genomics, developing companion diagnostics, and pioneering precision medicine approaches.

Roche's Basel headquarters offers exceptional quality of life in Switzerland, while US operations in South San Francisco provide Bay Area biotech ecosystem access.

The company's integration of pharma and diagnostics creates unique opportunities for computational biologists to see their work impact patient care from diagnosis through treatment.

🧬 Bioinformatics Focus

Roche's computational biology spans pharma research and diagnostics innovation. Key areas:

  • Personalized healthcare - developing companion diagnostics for targeted therapies like Herceptin (breast cancer), Tecentriq (immunotherapy),
  • Single - cell and spatial genomics - partnership with 10x Genomics, internal Roche platforms,
  • Clinical genomics - analyzing biomarkers from Phase I-IV trials across oncology, neuroscience, rare diseases,
  • Foundation Medicine integration - comprehensive genomic profiling for cancer patients (Roche acquired Foundation Medicine),
  • Digital pathology and AI - analyzing tissue images for tumor characterization. Notable programs include FoundationOne CDx (companion diagnostic), ventana digital pathology, and NAVIFY tumor board platform. Technical challenges include integrating multi-modal data (genomics, imaging, clinical), developing robust biomarkers for regulatory approval, and scaling personalized medicine globally. The diagnostics + pharma combination allows computational biologists to work on the full patient journey from early detection to treatment response monitoring.

📈 Career Growth & Development

Career Paths

Scientist Track

Scientist Senior Scientist Principal Scientist Distinguished Scientist

Management Track

Group Leader Senior Group Leader Director VP
💰

Compensation

Competitive base salaries are offered, along with performance bonuses (15-25% at senior levels) and stock appreciation rights.

📚

Development

Roche invests heavily in employee development through internal training academies, external coursework, and international rotations.

🔄

Mobility

Unique opportunities exist to rotate between Roche sites in Basel, Genentech in South San Francisco, and other global locations.

🤝

Network

The Roche/Genentech combined network provides extraordinary alumni connections across the global pharmaceutical industry.

🎯

Expertise

Computational biologists can gain experience in both drug development and diagnostics, a rare and highly valued combination.

Culture

Roche values both deep technical expertise and cross-functional leadership.